ATRIAL-NATRIURETIC-PEPTIDE AND CYCLIC 3'5'-GUANOSINE MONOPHOSPHATE AS INDICATORS OF FLUID VOLUME OVERLOAD IN CHILDREN WITH CHRONIC-RENAL-FAILURE

被引：12

作者：

LETTGEN, B ^{[1
]}

BALD, M ^{[1
]}

VALLEE, H ^{[1
]}

BONZEL, KE ^{[1
]}

RASCHER, W ^{[1
]}

机构：

[1] UNIV ESSEN GESAMTHSCH,KINDER & JUGENDMED KLIN,DEPT PAEDIAT NEPHROL,HUFELANDSTR 55,W-4300 ESSEN 1,GERMANY

来源：

PEDIATRIC NEPHROLOGY | 1992年 / 6卷 / 01期

关键词：

ATRIAL NATRIURETIC PEPTIDE; CYCLIC 3'5'-GUANOSINE MONOPHOSPHATE; CHRONIC RENAL FAILURE; HEMODIALYSIS; VOLUME OVERLOAD;

D O I：

10.1007/BF00856837

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Plasma atrial natriuretic peptide (ANP) and cyclic 3'5'-guanosine monophosphate (cGMP) were investigated as indicators of fluid volume overload in children and adolescents with chronic renal failure. Plasma ANP and cGMP were measured in both paediatric patients with chronic renal failure (n = 17, mean serum creatinine 371 +/- 242-mu-mol/l) and those with end-stage renal disease on haemodialysis (n = 18). cGMP was higher in children with chronic renal failure than in 45 healthy controls (1.0 +/- 0.4 vs 2.1 +/- 0.8 nmol/l, P < 0.01), whereas plasma ANP was similar (26.9 +/- 9.7 vs 34.0 +/- 12.3 pmol/l). Both ANP and cGMP were markedly elevated in children with end-stage renal disease before haemodialysis and fell significantly during dialysis. During dialysis body weight decreased by 1.6 +/- 0.7 kg, corresponding to 4.5 +/- 2.1% of body weight. Plasma ANP correlated positively with plasma cGMP in haemodialysed patients (r = 0.43, P < 0.05). Reduction in body weight and in mean arterial pressure correlated more closely with plasma ANP than with cGMP. Therefore, elevation of plasma ANP appears to indicate volume overload in children undergoing haemodialysis, but whether it can be used also in children with chronic renal failure requires further investigation.

引用

页码：60 / 64

页数：5

共 21 条

[1]

Chung H.M., Kluge R., Schrier R.W., Anderson R.J., Clinical assessment of extracellular fluid volume in hyponatremia, The American Journal of Medicine, 83, pp. 905-908, (1987)

[2]

Rascher W., Tulassay T., Lang R.E., Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure, Lancet, 2, pp. 303-305, (1985)

[3]

Czekalski S., Michel C., Dussaule J.C., Touraine P., Mignon F., Ardaillou R., Atrial natriuretic peptide and adaptation of sodium urinary excretion in patients with chronic renal failure, Clin Sci, 75, pp. 243-249, (1988)

[4]

Hasegawa K., Matsushita Y., Inoue T., Morii H., Ishibashi M., Yamaji T., Plasma levels of atrial natriuretic peptide in patients with chronic renal failure, J Clin Endocrinol Metal, 63, pp. 819-822, (1986)

[5]

Eisenhauer T., Talartschik J., Scheler F., Detection of fluid overload by plasma concentration of human atrial natriuretic peptide in patients with renal failure, Klin Wochenschr, 64, pp. 68-72, (1986)

[6]

Hartter E., Pacher R., Frass M., Woloszczuk W., Leither C., Plasma levels of atrial natriuretic peptide in volume expanded patients: response to fluid removal by continuous pump driven haemofiltration, Klin Wochenschr, 64, pp. 112-114, (1986)

[7]

Gerzer R., Heim J.M., Schutte B., Weil J., Cellular mechanisms of action of atrial natriuretic factor, Klin Wochenschr, 65, pp. 109-114, (1987)

[8]

Hamet P., Tremblay J., Pang S.C., Skuhherska R., Schiffin L., Garcia R., Chantin M., Genest J., Palmour R., Ervin F.R., Martin S., Goldwater R., Cyclic GMP as mediator and biological marker of atrial natriuretic factor, J Hypertens, 4, pp. 49-56, (1986)

[9]

Rascher W., Bald M., Kreis J., Tulassay T., Heinrich V., Scharer K., Atrial natriuretic peptide in infants and children, Hormone Research, 28, pp. 58-63, (1987)

[10]

Heim J-M, Gottmann K., Weil J., Haufe M.C., Gerzer R., Is cyclic GMP a clinically useful marker of ANF action?, Z Kardiol, 77, pp. 41-46, (1988)

← 1 2 3 →